Literature DB >> 2429019

Increased heterogeneity of serum thyroglobulin in thyroid cancer patients as determined by monoclonal antibodies.

B Heilig, M Hüfner, B Dörken, H Schmidt-Gayk.   

Abstract

We investigated the immunological heterogeneity of plasma Tg in thyroid cancer patients using monoclonal antibodies in an immunoradiometric assay and a conventional RIA system with a polyclonal rabbit antibody. The results were compared with measurements of plasma Tg in patients with nonmalignant disease. We can demonstrate an increased immunological heterogeneity in tumor patients compared with patients with non-malignant thyroid diseases. In one case the Tg value measured by a monoclonal test system exceeded the value obtained by a polyclonal RIA system in the same sample by a factor of 25. It has to be further investigated whether this increase in heterogeneity is of diagnostic value in the follow-up of thyroid cancer patients.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2429019     DOI： 10.1007/bf01732185

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN： 0023-2173


  8 in total

1.  Monoclonal antibodies to hog thyroglobulin recognizing disulfide-dependent conformational structures.

Authors:  E Kondo; Y Kondo
Journal:  Mol Immunol       Date:  1984-07       Impact factor: 4.407

2.  Isolation of desialylated and low-iodinated thyroglobulin in an experimental rat thyroid tumour.

Authors:  F Monaco; S Grimaldi; G Scuncio; M Andreoli
Journal:  Acta Endocrinol (Copenh)       Date:  1974-11

3.  Defective thyroglobulin synthesis in an experimental rat thyroid tumor: iodination and thyroid hormone synthesis in isolated tumor thyroglobulin.

Authors:  F Monaco; S Grimaldi; R Dominici; J Robbins
Journal:  Endocrinology       Date:  1975-08       Impact factor: 4.736

4.  Structural changes of carbohydrate chains of human thyroglobulin accompanying malignant transformations of thyroid glands.

Authors:  K Yamamoto; T Tsuji; O Tarutani; T Osawa
Journal:  Eur J Biochem       Date:  1984-08-15

5.  [The value of serum thyroglobulin determination in the after-care of patients with differentiated thyroid neoplasms].

Authors:  M Hüfner; H Pollmann; M Grussendorf; P Schenk
Journal:  Schweiz Med Wochenschr       Date:  1980-02-02

6.  Characterization of abnormal thyroglobulin in a transplantable rat thyroid tumor.

Authors:  M Izumi; H J Cahnmann; J Robbins
Journal:  Endocrinology       Date:  1977-05       Impact factor: 4.736

7.  The comparative value of serum thyroglobulin measurements and iodine 131 total body scans in the follow-up study of patients with treated differentiated thyroid cancer.

Authors:  M W Ashcraft; A J Van Herle
Journal:  Am J Med       Date:  1981-11       Impact factor: 4.965

8.  [Diagnostic value of 131I-whole body scintigraphy in the after care of differentiated thyroid cancer].

Authors:  M Hüfner; H P Stumpf; H J Hermann; B Kimmig
Journal:  Dtsch Med Wochenschr       Date:  1983-08-19       Impact factor: 0.628
  8 in total
  3 in total

1.  In vitro assays to test the interference of anti-thyroglobulin antibodies on thyroglobulin measurement.

Authors:  Deolinda Madureira; Susana Prazeres; Márcia São Pedro; Teresa Pereira; Ana Paula Font; Maria João Bugalho
Journal:  Endocrine       Date:  2008-03-29       Impact factor: 3.633

2.  Serum thyroglobulin (Tg) monitoring of patients with differentiated thyroid cancer using sensitive (second-generation) immunometric assays can be disrupted by false-negative and false-positive serum thyroglobulin autoantibody misclassifications.

Authors:  Carole Spencer; Ivana Petrovic; Shireen Fatemi; Jonathan LoPresti
Journal:  J Clin Endocrinol Metab       Date:  2014-12       Impact factor: 5.958

Review 3.  How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies.

Authors:  Carole Spencer; Jonathan LoPresti; Shireen Fatemi
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-10       Impact factor: 3.243
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.